Oscar Health Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.
06 Feb

Oscar Health (NYSE:OSCR) Full Year 2024 Results

Key Financial Results

  • Revenue: US$9.18b (up 57% from FY 2023).
  • Net income: US$25.4m (up from US$270.7m loss in FY 2023).
  • Profit margin: 0.3% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
  • EPS: US$0.11 (up from US$1.22 loss in FY 2023).
NYSE:OSCR Revenue and Expenses Breakdown February 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Oscar Health EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.5%.

In the last 12 months, the only revenue segment was Insurance - Life / Health contributing US$9.18b. Notably, cost of sales worth US$7.33b amounted to 80% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$1.76b (97% of total expenses). Explore how OSCR's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Insurance industry in the US.

Performance of the American Insurance industry.

The company's shares are down 5.6% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Oscar Health that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10